Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study (Q48565770)
Jump to navigation
Jump to search
scientific article published on 18 October 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study |
scientific article published on 18 October 2011 |
Statements
1 reference
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study (English)
1 reference
Bonaventura Clotet
1 reference
Jean-Michel Molina
1 reference
Anthony Lamarca
1 reference
Jaime Andrade-Villanueva
1 reference
Nathan Clumeck
1 reference
Ya-Pei Liu
1 reference
Lijie Zhong
1 reference
Nicolas Margot
1 reference
Andrew K Cheng
1 reference
Steven L Chuck
1 reference
Study 145 Team
1 reference
18 October 2011
1 reference
12
1 reference
1
1 reference
27-35
1 reference